A Sector at an Inflection Point
The EU pharmaceutical import and batch release landscape is undergoing a period of significant change, driven by converging pressures from regulatory modernisation, supply chain resilience concerns, technological advancement, and the shifting geography of global pharmaceutical manufacturing. For organisations operating in this space, understanding the direction and pace of these changes is not merely an academic exercise. The strategic decisions being made today about import infrastructure, QP capacity, testing arrangements, and supply chain architecture will determine how well organisations are positioned to operate efficiently and compliantly in a regulatory environment that will look materially different within the next five to ten years.
This article examines the principal trends shaping the future of EU pharmaceutical import and batch release, exploring both the regulatory changes already in motion and the broader structural shifts that are redefining how pharmaceutical products move into and through the EU market. It is intended for directors and senior regulatory affairs professionals who are responsible for long-term planning in organisations with EU import activities.
Regulatory Modernisation: The General Pharmaceutical Legislation Revision
The most significant regulatory development currently in progress for the EU pharmaceutical sector is the revision of the General Pharmaceutical Legislation, which includes the replacement of Directive 2001/83/EC with a new Regulation and an updated Directive. The proposals published by the European Commission include a number of provisions with direct implications for pharmaceutical importation and batch release, including changes to the QP certification framework, modifications to the requirements for repeat testing of imported batches, and updated provisions relating to manufacturing and import authorisations.
One of the most consequential proposed changes is the move toward more flexible QP certification approaches that recognise the increasing role of digital documentation and remote quality oversight. The traditional model, in which the QP reviews a physical or digital dossier at the import site, is already evolving in practice, but the new legislation is expected to provide a more explicit framework for remote and technology-enabled QP functions. Organisations that have already invested in the digital infrastructure for remote dossier management will be better positioned to take advantage of these developments than those still operating paper-based review processes.
The revision also addresses the Mutual Recognition Agreement landscape, with provisions intended to streamline the process for extending MRA coverage to additional third countries and for maintaining the currency of existing agreements as regulatory standards evolve. For importers with supply chains in countries not currently covered by MRAs, the prospect of expanded coverage represents a potential reduction in testing costs and release timelines, though the timescales for negotiating and implementing new agreements should not be assumed to be short.
Digitalisation of the Batch Release Process
Electronic Batch Records and QP Certification
The pharmaceutical industry’s transition from paper-based to electronic batch records is well underway in manufacturing but has been slower in the import and batch release function. The QP’s review of a batch release dossier has historically involved significant volumes of paper or PDF documentation, reviewed sequentially and manually cross-referenced across multiple documents. This process is time-consuming, resource-intensive, and creates bottlenecks that extend the time from batch arrival to market release.
The adoption of structured electronic batch records, in which the data elements of the dossier are captured in machine-readable formats rather than in unstructured documents, enables a more efficient and more consistent QP review process. Automated checks can flag missing data elements, out-of-specification results, or unresolved deviations before the QP begins their review, focusing the QP’s attention on the substantive quality questions rather than on document completeness checks. Over time, data analytics tools applied to structured batch data can also support more sophisticated risk-based approaches to QP review, with the level of detailed review calibrated to the risk profile of the specific batch.
Regulatory acceptance of electronic batch records for QP certification purposes is increasing. The EMA’s reflection papers on electronic batch records and the inclusion of digital documentation principles in GMP guidance updates signal a clear direction of travel. Organisations investing now in electronic batch record systems that are compliant with current guidance are building infrastructure that will align with, rather than resist, the regulatory expectations of the next decade.
Blockchain and Supply Chain Traceability
The application of blockchain technology to pharmaceutical supply chain traceability has attracted significant attention over the past several years, and while full-scale implementation remains more limited than early projections suggested, the underlying drivers of that interest are real and persistent. The falsified medicines challenge, the complexity of global pharmaceutical supply chains, and the regulatory emphasis on serialisation and track-and-trace all create demand for technologies that can provide reliable, tamper-evident records of a product’s journey from manufacturing site to patient.
For import and batch release operations specifically, blockchain-based documentation platforms offer the prospect of a shared, immutable record of the batch’s manufacturing and testing history that is accessible to all authorised parties, including the importer, the QP, the competent authority, and ultimately the marketing authorisation holder, without the delays and integrity risks associated with document transmission through conventional channels. The QP’s review of a blockchain-anchored batch record can be conducted with a higher degree of confidence in the authenticity of the documentation than is possible with document sets transmitted through email or document management systems without cryptographic verification.
Supply Chain Resilience and the Reshoring Debate
The disruptions to pharmaceutical supply chains experienced during and after the COVID-19 pandemic brought the geography of global pharmaceutical manufacturing into sharp focus for regulators, governments, and industry alike. The concentration of active pharmaceutical ingredient manufacturing in a small number of countries, and the resulting vulnerability of EU pharmaceutical supply to disruption at those sites, has prompted policy responses at both EU and member state level aimed at encouraging the reshoring or near-shoring of pharmaceutical manufacturing capacity.
For EU import operations, these policy trends create a complex set of strategic considerations. On one hand, increased EU-based or European-sourced manufacturing reduces the import dependency that current import operations are built around. On the other hand, the transition to more regionally distributed manufacturing is a long-term project that will take years to materially change the supply geography of most product categories, and in the interim, import operations will continue to be essential for maintaining supply. Organisations should plan for a supply chain landscape in which EU-based and third-country manufacturing coexist for an extended period, rather than assuming that reshoring will quickly eliminate the need for import infrastructure.
The regulatory response to supply chain resilience concerns also includes measures aimed at improving the early warning systems for supply disruptions, with importers required to notify competent authorities of anticipated shortages within defined timescales. These notification obligations add to the compliance infrastructure that import operations must maintain and should be reflected in the quality management systems and contractual arrangements that govern the importer’s relationships with its manufacturing and supply chain partners.
The Evolving QP Function
The role of the Qualified Person is evolving in ways that reflect both the changing regulatory framework and the changing nature of the pharmaceutical supply chains through which the QP function operates. The increasing complexity of advanced therapy medicinal products, biological products, and personalised medicines creates demand for QPs with highly specialised knowledge that goes well beyond the core pharmaceutical science background that the statutory qualifications require. Organisations developing or commercialising these product types must consider whether their QP capacity is genuinely matched to the technical demands of the products they are certifying.
The concept of QP networks, in which QPs at different organisations share intelligence, best practice, and regulatory insight through structured professional communities, is gaining traction as the complexity of the role increases. Professional bodies and regulatory authorities are both investing in the development of QP competency frameworks that go beyond the minimum statutory requirements and that provide a more granular picture of the expertise needed for different product types and supply chain configurations.
For organisations planning their import and batch release infrastructure for the medium and long term, staying ahead of these developments requires access to expertise that is both technically current and strategically aware. Inglasia’s specialist EU import and batch release services are delivered by professionals who monitor regulatory developments closely and apply that awareness to the practical challenges of import and batch release management.
Conclusion
The EU pharmaceutical import and batch release landscape is in a period of sustained change, driven by regulatory modernisation, digital transformation, supply chain resilience policy, and the evolving demands of increasingly complex product portfolios. Organisations that are investing now in the digital infrastructure, the QP capacity, and the supply chain architecture needed to operate effectively in this changing environment are building a competitive advantage that will compound as the changes mature. For a strategic conversation about how your organisation can position its import operations for the future, contact us and speak with our team.
